Antitumor activity of ZD6474 in a metastatic orthotopic brain tumor model

Molecular Medicine Reports

Volumn 1, Issue 3, 2008, Pages 343-346

  Kong, Doo Sik ^a   Kim, Mi Hyun ^a   Jeon, Ji Won ^a   Kim, Shi Yeon ^a   Maeng, Sup Kim ^b   Kyeung, Min Joo ^a   Park, Kwan ^a,c   Nam, Do Hyun ^a,c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Brain tumor; Epidermal growth facor receptor; Vascular endothelial growth factor receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE; VANDETANIB; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; BRAIN; BRAIN METASTASIS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; INTERNAL CAROTID ARTERY OCCLUSION; LUNG; MICROMETASTASIS; MOUSE; NONHUMAN; THERAPY EFFECT; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

MUS;

EID: 69249122910     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.1.3.343     Document Type: Article

References (17)

1. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002.
2. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999. (Pubitemid 29038270)
3. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36: 127-137, 1995.
4. Mendelsohn J: Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol Immunother 52: 342-346, 2003. (Pubitemid 36578028)
5. Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I and Raben D: ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys 64: 33-37, 2006. (Pubitemid 41831206)
6. Yokoi K, Kim SJ, Thaker P, Yazici S, Nam DH, He J, Sasaki T, Chiao PJ, Sclabas GM, Abbruzzese JL, Hamilton SR and Fidler IJ: Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. Neoplasia 7: 696-704, 2005. (Pubitemid 41099423)
7. Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G, Bianco R, Ryan A, Bianco AR, De Placido S, Ciardiello F and Tortora G: Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 11: 5639-5644, 2005. (Pubitemid 41060843)
8. Drevs J, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ and Esser N: The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 7: 347-354, 2004. (Pubitemid 40767936)
9. Giannelli G, Azzariti A, Sgarra C, Porcelli L, Antonaci S and Paradiso A: ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochem Pharmacol 71: 479-485, 2006. (Pubitemid 43077082)
10. Hanrahan EO and Heymach JV: Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 13: S4617-S4622, 2007.
11. Hoffmann S, Glaser S, Wunderlich A, Lingelbach S, Dietrich C, Burchert A, Muller H, Rothmund M and Zielke A: Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors - a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbecks Arch Surg 391: 589-596, 2006. (Pubitemid 44657740)
12. Leenders WP, Küsters B, Verrijp K, Maass C, Wesseling P, Heerschap A, Ruiter D, Ryan A and De Waal R: Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 10: 6222-6230, 2004. (Pubitemid 39287530)
13. Yano S, Muguruma H, Matsumori Y, Goto H, Nakataki E, Edakuni N, Tomimoto H, Kakiuchi S, Yamamoto A, Uehara H, Ryan A and Sone S: Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Clin Cancer Res 11: 8789-8798, 2005. (Pubitemid 43005930)
14. Yokoi K, Sasaki T, Bucana CD, Fan D, Baker CH, Kitadai Y, Kuwai T, Abbruzzese JL and Fidler IJ: Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 65: 10371-10380, 2005.
15. Yokoi K, Thaker PH, Yazici S, Rebhun RR, Nam DH, He J, Kim SJ, Abbruzzese JL, Hamilton SR and Fidler IJ: Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 65: 3716-3725, 2005. (Pubitemid 40616349)
16. Taghian A, De Vathaire F, Terrier P, Le M, Auquier A, Mouriesse H, Grimaud E, Sarrazin D and Tubiana M: Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys 21: 361-367, 1991.
17. Taghian A, Lespinasse F and Guichard ME: Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts. Int J Radiat Oncol Biol Phys 21: 1535-1540, 1991.